Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel compound efficacy in a humanized mouse model of psoriasis
NL-OMON35253Active, not recruiting
- Sponsor
- TNO
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of infliximab and tocilizumab in psoriasis and plaque psoriasis (3 arms), sponsored by TNO. Primary endpoints: Effect on psoriatic process in transplanted biopsies and Epidermal thickness. Started Nov 2011; status: active, not recruiting.
02
Drugs
infliximabtocilizumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on NL-OMON35253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35253.